GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Ghrelin up-regulates cartilage-specific genes via the ERK/STAT3 pathway in chondrocytes of patients with adolescent idiopathic scoliosis.
Liang. Zhuo-Tao ZT; Li. Jiong J; Rong. Rong- R; Wang. Yun-Jia YJ; Xiao. Li-Ge LG; Yang. Guan-Teng GT; Zhang. Hong-Qi HQ
Key Findings
- AIS patients have higher ghrelin and GHSR (ghrelin receptor) levels in their cartilage cells compared to controls.
- Adding ghrelin (or the GHRP‑6 agonist) to AIS chondrocytes increases cell proliferation and boosts cartilage‑specific genes (COLII, SOX9, ACAN) via activation of ERK1/2 and STAT3 (Ser727).
- Blocking the ghrelin receptor with [D‑Lys3]‑GHRP‑6 or inhibiting ERK1/2 with U0126 stops the ghrelin‑induced signaling and gene expression, showing ERK is upstream of STAT3 in this process.
Practical Outcomes
- For biohackers interested in joint or cartilage health, the data suggest that ghrelin‑activating peptides like GHRP‑6 could theoretically promote cartilage growth and repair. However, the findings are limited to lab‑grown cells from adolescent scoliosis patients, with no human dosing or safety information. Until clinical studies confirm benefits and safe protocols, using GHRP‑6 for cartilage support remains speculative and should be approached with caution.
Summary
The study found that higher levels of the hunger hormone ghrelin and its receptor are present in the cartilage cells of teens with scoliosis, and that giving ghrelin to these cells makes them grow and produce more cartilage proteins. This effect works through a specific cell signaling pathway (ERK/STAT3), and it disappears when the ghrelin receptor or the pathway is blocked.
Abstract
Adolescent idiopathic scoliosis (AIS) is a severe spinal deformity that often occurs during puberty. The occurrence of AIS is suggested to be related to abnormal development of cartilage. Our previous study found increased serum ghrelin levels in AIS patients that may linked to the development of AIS. However, whether ghrelin affects cartilage in AIS patients is unclear. We used quantitative real-time PCR (qRT-PCR) and immunohistochemistry to detect the expression of cartilage-specific genes and the ghrelin receptor, growth hormone secretagogue receptor (GHSR). The mRNA and protein levels of collagen II (COLII), SOX9, AGGRECAN (ACAN) and GHSR were higher in AIS patients than in controls. In addition, the protein levels of GHSR downstream signaling pathway members p-STAT3 (Ser727), and p-ERK1/2 were increased. Furthermore, we treated chondrocytes from AIS patients with 100 nM ghrelin, the cell proliferation assay and Western blotting showed that ghrelin promotes chondrocyte proliferation and enhances COLII, SOX9, ACAN, p-ERK1/2 and p-STAT3 expression, respectively. Interestingly, all these observed alterations were abolished by ghrelin + [D-Lys3]-GHRP-6 (a ghrelin receptor inhibitor) treatment. And after U0126 (an inhibitor of ERK1/2 phosphorylation) treatment, ERK1/2 and STAT3 (Ser727) phosphorylation was simultaneously suppressed indicating that ERK1/2 is an upstream pathway protein of STAT3 (Ser727). In conclusion, ghrelin plays an important role in upregulating cartilage-specific genes on AIS primary chondrocytes by activating ERK/STAT3 signaling pathway.
Study Information
pubmed
2019
2019-08-14T00:00:00.000Z
10.1016/j.bbrc.2019.08.044
18
33